Our most advanced candidate, RA01, could become the first preventive solution for infections associated with Gram-negative bacteria in the ICU. We have obtained data both in vitro and in vivo that prove the efficacy of our first candidate.
RemAb Therapeutics is developing, with the same technology, three more programs that point to other clinical needs not covered. These programs will be included in the portfolio soon.
PhD in Medicine (University Autonomous of Barcelona).
1990-1994: Assistant Professor of Surgery in the Thomas Starzl Transplantation Institute of the University of Pittsburgh, USA.
1996-2003 Director of Transplantation, in La Coruña University Hospital, Spain.
2003-act. Director of Critical Care Medicine at Bellvitge University Hospital, Spain.
Expert in transplantation and xenotransplantation systems, and in the role of antibodies in the rejection of allografts and xenografts, and in the development of infections.
Dr. Mañez holds 2 patents and is the author of 135 PubMed referenced articles and has 19 additional publications as Collaborator.
PhD in Molecular and Cellular Biology (Miguel Hernandez University, Spain).
His expertise is mainly linked to the protein biotechnology, microbiology, and immunology fields. He is an expert on the role of natural anti-glycan antibodies in the progression of infectious diseases and xenotransplantation.
He has been awarded different grants from the European Molecular Biology Organization, EMBO (2008); the International Union of Biochemistry and Molecular Biology, IUBMB (2006) and The Swiss Government Excellence Scholarships (2006).
He carries out consultant activities to local biotech companies. Dr. Bello holds 2 patents and is the author of several peer-reviewed scientific publications.
Graduate in Business Administration (University of Barcelona) with a double degree in international finance by Hogeschool van Utrecht. Started his career in financial positions and Consulting in PwC.
He has spent 13 years in Asia and he contributed in the opening and development of the activities in China for Werfen Group, as Financial Director and Operations Director.
He has provided provides tailor-made services and advice in the life science field, included early-stage healthcare projects, with go-to market, comprehensive transaction advice and funding. He counts with a strong network of industry contacts in Europe and Asia (from companies to investment banks).
BSc in Public Relations Communication degree (University of Barcelona)
MSc in Scientific Communication (Pompeu Fabra University, Barcelona)
MSc in Corporate Social Responsibility (Institut des Ressources Humaines, Paris)
More than 20 years of expertise in Health communication.
Chief Communications Officer (CCO) Novartis Group in Spain
Responsible for leading Reputation, Communication and CSR for the Group companies (Alcon, Sandoz, Novartis Farmacéutica, Novartis Consumer Health and Novartis Vaccines) (2007-2018)
President of the National Communication Association of Pharmaceutical Industry, ACOIF (2012-2014)
Member of Corporate Social Responsibility and General Secretary of the Board of Directors. Spanish National Communication’s Association, DIRCOM (2012-2014)
President of Spanish National Communication’s Association, DIRCOM. (2014-2018)
TOP 100 women leaders in Spain.
Industrial PhD en Medicine and Translational Research: Inmunology (Universidad de Barcelona)
MSc in Advanced Microbiology: Sanitary Specialty (University of Barcelona)
Previously, she has been working as a Laboratory technician in Envigo CRS and IDIBELL.
She is an expert on antibody quantification and purification, handling and conservation of biological samples, development of bactericidal assays, evaluation of the binding of antibodies by flow cytometry and biomass quantification.
MSc in Advanced Microbiology: Sanitary Specialty (University of Barcelona)
Previously, she has been working as a Laboratory analyst in the field of immunology and clinical trials.
She is an expert on antibody quantification and purification, handling and conservation of biological samples and file management.
Ph.D. in Biomedicine: Microbial Bioengineering (University of Barcelona).
Previously, she worked as Research Associate at Imperial College London and at Institute for Bioengineering of Catalonia (IBEC).
She is specialised in the host immunological response, the host-pathogen interaction, and in infectious diseases. She is author of several peer-reviewed scientific publications in the 1stQ of microbiology and immunology journals.
She has been awarded with the TecnioSpring INDUSTRY grant (2020) - Catalonia Trade & Investment and MSCA-COFUND project.
PhD in Biochemistry (Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, Russia).
She has experience in the field of immunology and biotechnology and participated in the development of a glycan array technology for the study of natural anti-glycan antibodies.
She Worked under Russian Academy of Sciences state grants and the Ministry of Healthcare national programs in collaboration with the National Medical Research Center for Obstetrics, Gynecology, and Perinatology, named after Academician V.I.Kulakov, N.N. Blockhin National Medical Research Centre of Oncology, N.D. Zelinsky Institute of Organic Chemistry.
She has been awarded with the Torres Quevedo del Subprograma Estatal de Incorporación- Ministerio de Ciencia e Innovación.
Bachelor of Medicine (Autonomous University of Barcelona).
Dr. Luria was Head of Safety and Efficacy of Drugs at the European Medicines Agency (EMA) during 2005-2012.
He is a recognized expert in regulatory systems and risk-benefit assessment (modeling, development and methodologies) and has been a professor at the University of California, San Francisco. In addition, he advises governments in Europe and Latin America and is a professor of regulation of the life sciences industry at IE Business School and professor at several other academic institutions in Europe and the United States. Prior to joining the EMA, he held leadership positions in the biopharmaceutical industry for more than eighteen years, covering international clinical development, pharmacovigilance, biostatistics and medical issues.
Ph.D. in Analytical Chemistry (Autonomous University of Barcelona).
Dr. Fábregas has extensive experience in management within the pharmaceutical industry, leading different disciplines related to chemistry, manufacturing and controls (CMC) which has supported the global development of pharmaceutical substances and products in the respiratory areas, central nervous system, gastrointestinal system and pain and inflammation.
From 1993 to 2010, permanent member of the R & D Management Committee and the R & D Leadership Committee in Almirall.
Professor at Rush Medical College, (Chicago, USA) where he studies the regeneration of ischemic myocardium, after myocardial infarction, induced by nanoparticles with αGal.
He discovered anti-αGal antibodies as the most abundant natural antibodies in humans. He also identified the α-gal epitope as the mammalian antigen that binds to anti-αGal antibodies, determined the unique evolution of anti-αGal antibodies and α-gal epitopes in primates and studied the molecular basis of this evolution.
He has developed methods to use anti-αGal antibodies in several therapies, including: immunotherapy against cancer, to increase immunogenicity of vaccines, acceleration of wound healing and burns and induction of tissue regeneration.
Head of the HIV Unit and director of the retrovirology laboratory "irsiCaixa" Foundation in the University Hospital "Germans Trias i Pujol", Spain.
He is part of the Drug Resistance Mutation Group of the International AIDS Society and is also a member of the Board of Directors of IAS Global.
He has published more than 500 articles in international journals, is co-director of AIDS CYBERJOURNAL and has been a member of the editorial board of AIDS Journal for 8 years. He is currently a reviewer for Lancet, JID, AIDS, CID, Antiviral Therapy, HIV Medicine, JAC and JAIDS.
His research focuses on the basic problems of glycobiology and the application of glyco-molecules in medicine. The main investigations include the synthesis of oligosaccharides and glycoconjugates, self-assembled peptides, carbohydrate-protein interactions, innate immunity to carbohydrates and the study of cell surface lectins and influenza virus.
He has founded two companies (Lectinity and Semiotik, Russia) and is the author of 359 scientific articles.
Head of the Department of Clinical Microbiology at the Ramón y Cajal University Hospital (Madrid, Spain), researcher at the Ramón y Cajal Institute for Health Research (IRYCIS) and associate professor of Clinical Microbiology.
Vice-president of the Spanish Society of Infectious Diseases and Clinical Microbiology, ad hoc member of the Steering Committee of the European Society of Clinical Microbiology and Infectious Diseases and president of the European Committee of Antimicrobial Susceptibility Tests. He is also associate editor of the journal Clinical Microbiology and Infection.
He has published more than 300 articles in medical journals and 45 book chapters.